Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 4,0614,080 of 20,252 grants

Completed NON-SBIR/STTR RPGS
A Phase 2 biomarker driven, Study of DB107, a Retroviral Replicating Vector, Combined With 5-FC in Patients with Recurrent Glioblastoma or Anaplastic Astrocytoma
NATIONAL CANCER INSTITUTE University of Miami School of Medicine United States 2023 – 2025

PROJECT SUMMARY High-grade gliomas are the most common primary brain tumors in adults that continue to have poor median 5-year survival rates despite maximal safe resection and che...

$2.05M
USD
Active NON-SBIR/STTR RPGS
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
NATIONAL CANCER INSTITUTE Indiana University Indianapolis United States 2023 – 2028

Project Abstract Cancer immunotherapy is a promising approach for cancers with no or limited specific targeted therapies. Various forms of immunotherapy, including checkpoint block...

$4.44M
USD
Active NON-SBIR/STTR RPGS
Regulation of the tumor microenvironment by DNA damage repair proteins
NATIONAL CANCER INSTITUTE San Diego State University United States 2023 – 2028

PROJECT SUMMARY Background ER+ breast cancer accounts for 2/3 of invasive breast cancer cases diagnosed in the world today. In patients, ~12% of ER+ tumors have complete loss of ML...

$1.85M
USD
Active NON-SBIR/STTR RPGS
Delineate the Role of GSTP1 in Advanced Prostate Cancer
NATIONAL CANCER INSTITUTE University of California Los Angeles United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT Prostate cancer is the second leading cause of cancer associated deaths in men in the United States. The first line of treatment for men with advanced meta...

$4.26M
USD
Active NON-SBIR/STTR RPGS
Role of metabolic crosstalk in determining immunity during tumor progression
NATIONAL CANCER INSTITUTE Brigham and Women'S Hospital United States 2023 – 2028

PROJECT SUMMARY Tumor cells and infiltrating immune cells co-evolve during the course of tumor progression, with the immune system progressively losing its efficacy as tumors advan...

$4.69M
USD
Active NON-SBIR/STTR RPGS
Regulation of the tumor microenvironment by DNA damage repair proteins
NATIONAL CANCER INSTITUTE San Diego State University United States 2023 – 2028

PROJECT SUMMARY Background ER+ breast cancer accounts for 2/3 of invasive breast cancer cases diagnosed in the world today. In patients, ~12% of ER+ tumors have complete loss of ML...

$3.99M
USD
Active NON-SBIR/STTR RPGS
Delineate the Role of GSTP1 in Advanced Prostate Cancer
NATIONAL CANCER INSTITUTE University of California Los Angeles United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT Prostate cancer is the second leading cause of cancer associated deaths in men in the United States. The first line of treatment for men with advanced meta...

$4.67M
USD
Active NON-SBIR/STTR RPGS
Tumor and immune determinants of effective anti-tumor immunity in renal cell carcinoma
NATIONAL CANCER INSTITUTE Yale University United States 2023 – 2028

PROJECT SUMMARY Immune checkpoint inhibitors (ICIs) targeting the PD-1 pathway have transformed the management of many advanced cancers, including renal cell carcinoma (RCC), but m...

$6.57M
USD
Active NON-SBIR/STTR RPGS
Role of metabolic crosstalk in determining immunity during tumor progression
NATIONAL CANCER INSTITUTE Brigham and Women'S Hospital United States 2023 – 2028

PROJECT SUMMARY Tumor cells and infiltrating immune cells co-evolve during the course of tumor progression, with the immune system progressively losing its efficacy as tumors advan...

$5.14M
USD
Completed NON-SBIR/STTR RPGS
A Phase 2 biomarker driven, Study of DB107, a Retroviral Replicating Vector, Combined With 5-FC in Patients with Recurrent Glioblastoma or Anaplastic Astrocytoma
NATIONAL CANCER INSTITUTE University of Miami School of Medicine United States 2023 – 2025

PROJECT SUMMARY High-grade gliomas are the most common primary brain tumors in adults that continue to have poor median 5-year survival rates despite maximal safe resection and che...

$1.79M
USD
Completed NON-SBIR/STTR RPGS
Elucidating the relevance of BARD1-PLK1 interaction in PDAC and response to therapy
NATIONAL CANCER INSTITUTE Thomas Jefferson University United States 2023 – 2025

ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with limited treatment options. The overall 5-year survival rate is only 11% and there is an unmet need for...

$780K
USD
Active NON-SBIR/STTR RPGS
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
NATIONAL CANCER INSTITUTE Indiana University Indianapolis United States 2023 – 2028

Project Abstract Cancer immunotherapy is a promising approach for cancers with no or limited specific targeted therapies. Various forms of immunotherapy, including checkpoint block...

$4.67M
USD
Completed NON-SBIR/STTR RPGS
Regulation of the tumor microenvironment by DNA damage repair proteins
NATIONAL CANCER INSTITUTE Sanford Burnham Prebys Medical Discovery... United States 2023 – 2024

PROJECT SUMMARY Background ER+ breast cancer accounts for 2/3 of invasive breast cancer cases diagnosed in the world today. In patients, ~12% of ER+ tumors have complete loss of ML...

$3.13M
USD
Completed OTHER RESEARCH-RELATED
Dietary prevention for colorectal cancer: targeting the bile acid/gut microbiome axis
NATIONAL CANCER INSTITUTE Harvard School of Public Health United States 2023 – 2025

PROJECT SUMMARY / ABSTRACT Diet is an established etiologic factor for colorectal cancer (CRC) and is estimated to account for more than 40% of CRC cases and deaths. Despite severa...

$1.2M
USD
Active NON-SBIR/STTR RPGS
Intersection of autophagy and vesicle trafficking in Her2-positive breast cancer
NATIONAL CANCER INSTITUTE University of Cincinnati United States 2023 – 2028

Breast cancer is the most common malignancy among US women and remains a major health threat with high incidence and lethality due to therapeutic resistance and metastasis. Breast...

$4.08M
USD
Active NON-SBIR/STTR RPGS
Dual Kinase and LSD1 Inhibition in Acute Myeloid Leukemia
NATIONAL CANCER INSTITUTE Oregon Health & Science University United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT Kinase inhibitor therapy has made a minimal impact on the clinical treatment of patients with Acute Myeloid Leukemia (AML). We have shown that inhibition o...

$4.85M
USD
Completed OTHER RESEARCH-RELATED
Dietary prevention for colorectal cancer: targeting the bile acid/gut microbiome axis
NATIONAL CANCER INSTITUTE Harvard School of Public Health United States 2023 – 2025

PROJECT SUMMARY / ABSTRACT Diet is an established etiologic factor for colorectal cancer (CRC) and is estimated to account for more than 40% of CRC cases and deaths. Despite severa...

$1.24M
USD
Active NON-SBIR/STTR RPGS
Improving Understanding of Quality End of Life Care Using a Dyadic Approach
NATIONAL CANCER INSTITUTE Case Western Reserve University United States 2023 – 2028

Project Summary/Abstract There is strong national consensus about the need to deliver high-quality care at the end of life (EOL) for patients with advanced (distant metastasis) can...

$6.92M
USD
Active NON-SBIR/STTR RPGS
An urinary drug disposing approach for treatment of bladder Cancer
NATIONAL CANCER INSTITUTE Weill Medical Coll of Cornell Univ United States 2023 – 2028

Project Summary Most bladder cancer (BC) patients are diagnosed at an early stage. More than 80% of cases are non-muscle invasive BC (NMIBC). The standard treatment involves removi...

$6.66M
USD
Active TRAINING, INDIVIDUAL
Investigating the role of melanoma-adipocyte cell junctions in heterotypic communication and tumor progression
NATIONAL CANCER INSTITUTE Sloan-Kettering Inst Can Research United States 2023 – 2026

PROJECT SUMMARY Melanoma is the most lethal skin cancer. Few treatment options exist for patients with metastatic disease. Upon tumorigenesis, melanoma cells invade into dermal and...

$476.9K
USD